Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term effects of AZD5363 (AKT inhibitor) on AKT pathway biomarkers in breast cancer (STAKT)
2012-005019-14Phase 2Completed
- Sponsor
- University of Nottingham
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capivasertib in breast cancer, sponsored by University of Nottingham. Started Apr 2013; status: completed.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-005019-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005019-14.